Source link : https://newshealth.biz/health-news/alzheimers-benefits-continue-with-donanemab-for-3-years-long-term-data-show/
(MedPage Today) — TORONTO — The clinical benefits of donanemab (Kisunla) continued over 3 years in people with early symptomatic Alzheimer’s disease, data from the long-term extension of the TRAILBLAZER-ALZ 2 trial suggested. Compared with… Source link : https://www.medpagetoday.com/meetingcoverage/aaic/116791 Author : Publish date : 2025-08-01 18:42:00 Copyright for syndicated content belongs to the linked Source.
The post Alzheimer’s Benefits Continue With Donanemab for 3 Years, Long-Term Data Show first appeared on News Health.
—-
Author : News Health
Publish date : 2025-08-01 18:42:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8